Reason for request
Re-assessment of the actual benefit (AB) and the level of improvement in actual benefit (IAB) at the request of the applicant.
Clinical Benefit
| Low |
The actual benefit of MYOZYME remains low in the treatment of late-onset Pompe disease. |
Clinical Added Value
| minor |
The improvement in actual benefit remains minor (level IV) in the treatment of late-onset Pompe disease. |
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
X0U1RR5PMgreNRQY
Listen
